Robust Drug Pipeline Highlights Specialty Pharmacy Week in Review
Top stories of the week on Specialty Pharmacy Times from April 20 to April 24.
Top stories of the week on Specialty Pharmacy Times from April 20 to April 24.
Specialty Drugs Dominate Late-Stage Pipeline
Record number of orphan drugs approved in 2014.
http://www.specialtypharmacytimes.com/news/Specialty-Drugs-Dominate-Late-Stage-Pipeline
Adherence is Paramount in Era of Rising Specialty Drug Costs
Catamaran chief medical officer discusses various trends that will impact specialty medications into the future.
MS Drug Combination Repairs Damaged Brain Cells, Reverses Paralysis
Topical medications that treat skin conditions prompt stem cells in the brain to repair damage.
Pfizer’s Lung Cancer Drug Receives Breakthrough Designation
Pfizer seeking to expand approved use of Xalkori to patients with ROS1-positive non-small cell lung cancer.
Protein Inhibition Therapy Holds Promise for Treating Several Cancer Types
Regulating PD-L1 protein that helps cancer evade immune system suggests new therapeutic approach.
Extending Dose of Multiple Sclerosis Drug Safe and Effective
Pushing treatment with natalizumab from 4 weeks up to 8 weeks shows promising results.
Multiple Sclerosis Drug Effective Fighting HIV Viral Reservoir
Medication also used in treatment of Crohn’s disease effective at blocking pathways.
Prostate Cancer Drug Label Updated with Survival Data
Study showed a median overall survival of nearly 3 years with Zytiga plus prednisone.
http://www.specialtypharmacytimes.com/news/Prostate-Cancer-Drug-Label-Updated-with-Survival-Data
Racial Disparities in Cancer Death Rate Declining
Mortality gap in cancer deaths among African Americans and Caucasians may eventually disappear.
http://www.specialtypharmacytimes.com/news/Racial-Disparities-in-Cancer-Death-Rate-Declining
Otezla Shows Promise in Treatment of Rare Inflammatory Disease
Treatment found to improve several measures of disease activity and quality of life in patients with Behçet's disease.
